Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Kaiyue DiaoDuolao WangZhongxiu ChenXi WuMin MaYe ZhuLi ZhangHua WangMian WangSen HeChen LiQiao DengTing YanTao WuLu TangBao-Tao HuangJiayu SunYong HePublished in: Clinical cardiology (2021)
The results of the PERI-STEMI trial are expected to provide CMR evidence on whether ARNI could benefit patients with STEMI, so as to facilitate the strategy of CMR-based risk stratification and therapy selection for these patients. PERI-STEMI is registered at ClinicalTrials.gov (NCT04912167).
Keyphrases
- st elevation myocardial infarction
- percutaneous coronary intervention
- randomized controlled trial
- st segment elevation myocardial infarction
- ejection fraction
- acute myocardial infarction
- study protocol
- left ventricular
- coronary artery disease
- acute coronary syndrome
- end stage renal disease
- newly diagnosed
- aortic stenosis
- heart failure
- clinical trial
- peritoneal dialysis
- stem cells
- phase iii
- atrial fibrillation
- open label
- bone marrow
- patient reported
- phase ii
- transcatheter aortic valve replacement